查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2001034

癌症免疫疗法药物研发外包市场：按服务类型、治疗方法、工作流程阶段和最终用户划分－2026年至2032年全球市场预测

Cancer Immunotherapy Drug Discovery Outsourcing Market by Service Type, Therapeutic Modality, Workflow Stage, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年癌症免疫疗法药物开发外包市值为 9,622.7 亿美元，预计到 2026 年将成长至 1.08621 兆美元，年复合成长率为 14.15%，到 2032 年将达到 2.43162 兆美元。

主要市场统计数据
基准年 2025 9622.7亿美元
预计年份：2026年 1.08621兆美元
预测年份：2032年 24316.2亿美元
复合年增长率 (%) 14.15%

全面概述了外包为何已成为癌症免疫疗法药物发现和转化开发的战略必要性。

本文引言部分为希望了解癌症免疫疗法药物研发外包实践演变的读者提供了一个策略框架，使其能够获得简洁而全面的概述。细胞工程、核酸平台和免疫调节生技药品领域的最新进展，重新定义了赞助公司将技术任务外包给外部合作伙伴的方式和地点。这些变化反映了整个产业在缩短研发週期的同时，维持日益复杂的转换计画所需的科学严谨性的更广泛需求。

一个策略性的技术转折点：重新定义癌症免疫疗法药物发现和开发中的合作伙伴选择和能力要求。

该领域的变革性变化源自于科学突破与商业性压力的交汇，强调敏捷性和技术深度。随着CAR-T细胞疗法、RNA疫苗和新一代查核点调控等治疗方法的日益成熟，对外部合作伙伴的技术需求也不断提高。申办方日益寻求涵盖从先导化合物发现到临床前评估（支持IND申报）乃至临床阶段支持的一体化服务，这反映出他们倾向于选择数量较少但能力更强的合作伙伴，以管理复杂的、特定治疗方法的工作流程。

分析 2025 年贸易政策措施如何从结构上影响免疫疗法计画的采购韧性、供应商多元化和製造本地化。

美国于2025年实施的关税措施的累积影响，为参与免疫疗法开发外包的相关人员带来了成本压力和物流方面的限制。这些措施影响了专用试剂、一次性组件和某些生技药品相关设备的进口，进而影响了供应商选择和库存管理。严重依赖跨境供应链的机构面临着更长的前置作业时间，并且必须重新评估关键原材料的储备，尤其是在需要客製化细胞处理耗材和病毒载体组件的治疗方法。

将服务能力、治疗方式、工作流程阶段和最终用户优先顺序与可操作的外包策略联繫起来的详细细分见解。

关键的细分洞察揭示了不同服务类型、治疗模式、工作流程阶段和最终用户之间的策略重点和技术依赖性差异，从而能够基于这些洞察做出最佳采购决策。从服务类型角度来看，临床开发服务需要具备涵盖 I 期、II 期和 III 期的详细通讯协定设计和执行能力。同时，数据管理和生物统计学越来越侧重于生物资讯学、临床数据管理和统计分析，以提取转化讯号。生产支援强调 CMC 优化和製程开发，以实现可扩展的生产，而临床前服务则优先考虑先导化合物的发现，包括稳健的标靶识别策略、先导化合物优化和临床前安全性评估。监管支持在 IND 申请协助和监管策略咨询方面仍然至关重要，尤其是在新的治疗模式改变了监管机构对可比性和疗效测试的要求的情况下。

影响美洲、欧洲、中东、非洲和亚太地区地域优化外包策略的区域趋势和能力。

区域趋势影响着申办方的外包策略，主要归因于各大区域在监管协调、人才储备和基础建设成熟度等方面的差异。在美洲，临床试验中心的集中、成熟的合约研发生产机构（CDMO）的存在，以及创投公司和大型企业建构的强大投资生态系统，促进了先进治疗方法的快速应用。垂直整合的伙伴关係关係，整合了製程开发、GMP生产和后期临床支持，为这些疗法提供了强大支撑。这种环境有利于那些寻求快速进入临床阶段并需要整合分析能力以支持适应性测试设计的申办者。

癌症免疫疗法外包生态系统中成功服务供应商的竞争差异化因素和伙伴关係模式

对主要企业的分析凸显了竞争格局的现状：技术专长、平台整合以及能够降低专案风险的伙伴关係模式是企业实现差异化的关键所在。领先的供应商正投资于特定疗法的检测组合和内部生产技术，以支持CAR-T细胞疗法和溶瘤病毒等复杂疗法。此外，他们也透过整合先进的资料管理和生物资讯服务来强化自身的价值提案，将高维度生物学测量结果转化为符合监管要求的证据。

为采购和研发领导者提供切实可行的优先建议，以增强韧性并加速免疫疗法计画。

针对行业领导者的可操作建议强调了增强专案韧性和加速转化研究进展的实际步骤。首先，优先考虑能够提供深厚的、特定疗法专业知识的伙伴关係。例如，在细胞疗法和病毒载体专案中，选择在CMC优化和GMP製程开发方面拥有良好业绩记录的供应商，以降低规模化生产的风险。其次，在专案规划的早期阶段整合资料管理和进阶生物统计学，以便在样本采集、检测方法选择和生物资讯流程中产生符合监管要求的终点指标，从而实现适应性决策。

我们透明严谨的调查方法，结合对关键相关人员的访谈、二手资料的整合和结构化检验，为可操作的结论提供了支持。

本分析的调查方法结合了结构化的初步研究、专家检验和针对性的次要研究，以确保研究的严谨性和相关性。初步资料收集包括对研发部门高阶领导、临床营运经理、监管负责人和服务供应商高阶主管的访谈，以了解实际决策标准和营运限制。这些访谈为揭示能力差距、典型的供应商合作模式以及不断变化的资料管理和生物统计支持期望奠定了基础。

一份简洁、全面的分析报告，重点阐述了免疫疗法药物发现和开发外包的策略意义、营运重点和基本考虑因素。

总之，癌症免疫疗法药物发现和开发的外包模式正变得更加战略化、专业化和数据主导。申办者现在期望外部合作伙伴能够提供从药物发现阶段到临床阶段的整合能力，尤其着重于CMC製程开发、特异性疗法检测方法开发和进阶分析。政策变化和供应链趋势凸显了地理多元化的重要性，以及製定稳健的筹资策略以确保专案进度和产品品质的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：癌症免疫疗法药物研发外包市场：依服务类型划分

  • 临床开发服务
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 资料管理与生物统计学
    • 生物资讯学
    • 临床数据管理
    • 统计分析
  • 製造支持
    • CMC优化
    • 製程开发
  • 临床前服务
    • 点击量和潜在客户开发
    • 先导药物最适化
    • 临床前安全性评估
    • 目标识别
  • 药物支持
    • IND申请支持
    • 监理策略咨询

第九章：癌症免疫疗法药物研发外包市场：依治疗方法划分

  • 癌症疫苗
    • 树突细胞疫苗
    • DNA疫苗
    • 胜肽疫苗
    • RNA疫苗
  • CAR-T细胞疗法
    • BCMA靶点
    • CD19标靶
  • 查核点抑制剂
    • CTLA-4抑制剂
    • PD-1抑制剂
    • PD-L1抑制剂
  • 细胞激素疗法
    • 集落刺激因子
    • 干扰素
    • 白细胞介素
  • 单株抗体
    • 嵌合体
    • 完全人形
    • 人性化
    • 小鼠来源
  • 溶瘤病毒疗法
    • 基于腺病毒的
    • HSV 基础
    • 基于呼肠孤病毒

第十章：癌症免疫疗法药物研发外包市场：依工作流程阶段划分

  • 临床阶段
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 发展阶段
    • IND申请准备检查
    • 临床前开发
  • 药物发现阶段
    • 命中发现
    • 命中检验
    • 先导化合物搜寻
    • 目标识别
  • 核准后阶段
    • 药物安全监测
    • 第四阶段试验

第十一章：癌症免疫疗法药物开发外包市场：以最终用户划分

  • 学术研究机构
  • 生技公司
  • 政府附属研究机构
  • 製药公司

第十二章：癌症免疫疗法药物研发外包市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：癌症免疫疗法药物研发外包市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：癌症免疫疗法药物研发外包市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国癌症免疫疗法药物开发外包市场。

第十六章：中国癌症免疫疗法药物研发外包市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • BPS Bioscience, Inc.
  • Celentyx Ltd.
  • Charles River Laboratories International, Inc.
  • Covance, Inc.
  • Crown Bioscience, Inc.
  • Curia Inc.
  • Dalton Pharma Services
  • DiscoverX Corporation
  • Eurofins Scientific
  • Evotec SE
  • Explicyte
  • Genscript BIoTech Corporation
  • HD Biosciences Co., Ltd.
  • Horizon Discovery Group PLC
  • ImmunXperts SA
  • Jubilant Life Sciences Limited
  • Labcorp
  • Oncodesign Precision Medicine Opm SA
  • Personalis, Inc.
  • Promega Corporation
  • STC Biologics Inc.
  • TCG Lifesciences Pvt. Limited
  • WuXi AppTec Co., Ltd.
Product Code: MRR-205091A88709

The Cancer Immunotherapy Drug Discovery Outsourcing Market was valued at USD 962.27 billion in 2025 and is projected to grow to USD 1,086.21 billion in 2026, with a CAGR of 14.15%, reaching USD 2,431.62 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 962.27 billion
Estimated Year [2026] USD 1,086.21 billion
Forecast Year [2032] USD 2,431.62 billion
CAGR (%) 14.15%

Comprehensive contextual overview explaining why outsourcing has become a strategic imperative for cancer immunotherapy drug discovery and translational development

The introduction sets the strategic frame for readers who need a concise but comprehensive orientation to the evolving practice of outsourcing in cancer immunotherapy drug discovery. Over recent years, advances in cellular engineering, nucleic acid platforms, and immune-modulating biologics have redefined where and how sponsor organizations allocate technical work to external partners. These shifts reflect a broader industry imperative: to compress timelines while preserving the scientific rigor required for increasingly complex translational programs.

This report opens by articulating the primary drivers that compel companies to outsource, including the need for specialized preclinical assay suites, scalable manufacturing processes for cell and gene therapies, and the bioinformatics infrastructure necessary to manage high-dimensional translational data. It also highlights the counterbalances sponsors face, such as regulatory complexity, supply chain fragility, and rising expectations for quality and reproducibility. The introduction therefore positions outsourcing not merely as a cost-management tool but as a strategic instrument for capability augmentation, risk sharing, and accelerated learning across discovery, development, and early clinical proof-of-concept.

Strategic and technological inflection points reshaping partner selection and capability requirements across cancer immunotherapy discovery and development

Transformative shifts in the landscape are driven by converging scientific breakthroughs and commercial pressures that reward agility and technical depth. The maturation of modalities such as CAR T cell therapies, RNA-based vaccines, and next-generation checkpoint modulation has expanded the technical scope required of external partners. Sponsors increasingly demand integrated offerings that span hit and lead discovery through IND-enabling preclinical assessments and clinical stage support, reflecting a preference for fewer, more capable collaborators who can manage complex modality-specific workflows.

In parallel, technological enablers such as single-cell sequencing, multiplexed immunophenotyping, and machine learning-driven bioinformatics have raised the bar for data management and biostatistics support. As a result, the market is experiencing a clearer segmentation between providers that offer advanced analytics and those that focus on traditional wet-lab services. These trends are prompting a redefinition of partnerships: successful vendors now demonstrate not only technical competence in preclinical safety assessment, CMC optimization, or process development, but also robust data integration, regulatory strategy, and commercialization support. Consequently, sponsors are reorganizing their sourcing strategies to prioritize partners who can co-design experiments, translate complex translational signals into regulatory-ready dossiers, and scale manufacturing processes from early development to clinical and post-approval stages.

Analysis of how 2025 trade policy actions have structurally influenced sourcing resilience, supplier diversification, and manufacturing localization in immunotherapy programs

The cumulative impact of United States tariffs implemented in 2025 introduced discrete cost pressures and logistical constraints for stakeholders engaged in outsourced immunotherapy development. These measures affected the importation of specialized reagents, single-use components, and certain biologics-related hardware, which in turn influenced supplier selection and inventory practices. Organizations that relied heavily on cross-border supply chains experienced increased lead times and needed to reassess buffer stocks for critical inputs, particularly for modalities requiring bespoke cell-processing consumables and viral vector components.

In response, many sponsors accelerated efforts to localize key manufacturing steps or to diversify the supplier base so that essential CMC optimization and process development activities could continue unimpeded. Regulatory interactions became more prominent in vendor evaluation as sponsors sought assurance that documentation could withstand jurisdictional scrutiny if production footprints shifted. Additionally, the tariff environment highlighted the value of service models that reduce dependency on imported hardware by offering turnkey solutions and onshore clinical development services. Overall, the policy changes reinforced a strategic pivot toward resilient, geographically diversified outsourcing strategies that integrate procurement foresight with technical and regulatory mitigation plans.

In-depth segmentation insights that connect service capabilities, therapeutic modalities, workflow stages, and end-user priorities to practical outsourcing strategies

Key segmentation insights reveal how strategic priorities and technical dependencies vary by service type, therapeutic modality, workflow stage, and end user, informing tailored sourcing decisions. In the domain of service type, clinical development services require deep protocol design and execution capabilities across Phase I, Phase II, and Phase III, while data management and biostatistics increasingly center on bioinformatics, clinical data management, and statistical analysis to extract translational signals. Manufacturing support emphasizes CMC optimization and process development to enable scalable production, and preclinical services prioritize hit and lead discovery, lead optimization, and preclinical safety assessment with robust target identification strategies. Regulatory affairs support remains essential for IND filing support and regulatory strategy consulting, especially when novel modalities change the regulatory expectations for comparability and potency assays.

Therapeutic modality exerts a strong influence on vendor selection and operational risk. Cancer vaccines span dendritic cell, DNA, peptide, and RNA platforms each with distinct formulation and immunogenicity testing requirements. CAR T cell therapy programs differentiate technical needs between BCMA-targeted and CD19-targeted constructs, influencing vector choice and potency assays. Checkpoint inhibitors present distinct pathways based on CTLA-4, PD-1, and PD-L1 mechanisms, requiring tailored pharmacodynamic and biomarker strategies. Cytokine therapies demand expertise across colony stimulating factors, interferons, and interleukins, while monoclonal antibodies vary across chimeric, fully human, humanized, and murine formats with corresponding CMC implications. Oncolytic virus therapy further segments by platform, including adenovirus, HSV, and reovirus based approaches, each with unique GMP requirements for vector manufacturing and release testing.

Workflow stage segmentation clarifies where external expertise delivers the highest marginal value. Discovery-stage activities such as hit discovery, hit validation, lead discovery, and target identification benefit from specialized assay platforms and rapid iteration. Development-stage work focused on IND-enabling studies and preclinical development requires cross-functional coordination between toxicology, analytical development, and process engineers. Clinical stage initiatives across Phase I-III rely on clinical operations depth, while post-approval stage responsibilities emphasize pharmacovigilance and Phase IV studies that sustain safety surveillance and label expansion. Finally, end users drive different partnership dynamics: academic research institutes often seek modular, hypothesis-driven services; biotechnology companies prioritize speed and flexibility; government research institutes emphasize reproducibility and public health impact; and pharmaceutical companies demand integrated programs that de-risk later-stage regulatory submission and commercialization.

Regional dynamics and capability contrasts that inform geographically optimized outsourcing strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics shape how sponsors approach outsourcing, as factors such as regulatory harmonization, talent pools, and infrastructure maturity differ across major geographies. In the Americas, a concentration of clinical trial sites, established CDMOs, and deep venture and corporate investment ecosystems have fostered rapid adoption of advanced modalities and supported vertically integrated partnerships that combine process development, GMP manufacturing, and late-stage clinical support. This environment favors sponsors seeking speed to clinic and integrated analytics capabilities that can support adaptive trial designs.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and centers of excellence that enables targeted collaborations for specialized assay development, biologics manufacturing, and translational immuno-oncology research. Variability in national regulatory timelines and reimbursement environments prompts sponsors to design geographically optimized development plans that leverage local scientific expertise while addressing cross-border regulatory convergence. In contrast, Asia-Pacific has emerged as a hub for scalable manufacturing capacity, a growing base of skilled cell and gene therapy scientists, and an expanded clinical trial infrastructure. Governments and private investors in the region have prioritized biotech industrialization, which has translated into increased availability of CMC optimization services, process development talent, and onshore vector manufacturing options. Sponsors operating across these regions adopt hybrid strategies that combine local execution for cost and capacity advantages with centralized coordination for regulatory alignment and data governance.

Competitive differentiation and partnership models that define successful service providers in the cancer immunotherapy outsourcing ecosystem

Key companies insights point to a competitive environment where differentiation stems from technical specialization, platform integration, and partnership models that reduce program risk. Leading providers invest in modality-specific assay portfolios and in-house manufacturing technologies to support complex modalities such as CAR T cell therapies and oncolytic viruses. They also strengthen their value proposition by embedding advanced data management and bioinformatics services that convert high-dimensional biological readouts into regulatory-grade evidence.

Strategic alliances are increasingly common, with commercial biotechs, academic spinouts, and service providers forming project-based consortia to accelerate IND-enabling activities. Top-performing vendors demonstrate transparent quality systems, validated analytics, and the ability to scale CMC processes from bench to clinical lots. In parallel, a subset of organizations has differentiated by offering regulatory strategy consulting alongside IND filing support, thereby minimizing handoffs and accelerating submission readiness. The market reward goes to those firms that can demonstrate reproducible assay transfer, robust comparability strategies, and an integrated approach to managing manufacturing variability, supply continuity, and regulatory expectations across jurisdictions.

Practical and prioritized recommendations that procurement, research, and development leaders can implement to enhance resilience and accelerate immunotherapy programs

Actionable recommendations for industry leaders emphasize pragmatic steps to strengthen program resilience and accelerate translational progress. First, prioritize partnerships that offer modality-aligned depth; for example, select vendors with proven CMC optimization and GMP process development experience for cell and viral vector programs to reduce scale-up risk. Second, integrate data management and advanced biostatistics early in program planning so that sample collection, assay selection, and bioinformatics pipelines produce regulatory-grade endpoints and enable adaptive decision-making.

Third, reassess supply chain strategies by incorporating regional supplier diversification and buffer inventories for critical single-use components and reagents; this will mitigate exposure to external tariff or logistics shocks. Fourth, embed regulatory strategy consulting with technical workstreams to ensure that assay development, comparability plans, and documentation meet jurisdictional expectations ahead of IND submission. Fifth, consider modular contracting models that allow for phased scope increases as development milestones are met, enabling sponsors to maintain flexibility while securing priority access to vendor capacity. Finally, invest in vendor audits and technical transfer protocols that emphasize reproducibility and documentation quality, thereby reducing downstream delays and facilitating faster approvals.

Transparent and rigorous research methodology combining primary stakeholder interviews, secondary literature synthesis, and structured validation to support actionable conclusions

The research methodology underpinning this analysis combined structured primary research, expert validation, and targeted secondary review to ensure rigor and relevance. Primary data collection included interviews with senior R&D leaders, clinical operations heads, regulatory strategists, and service provider executives to capture real-world decision criteria and operational constraints. These discussions provided the foundation for mapping capability gaps, typical vendor engagement models, and the evolving expectations for data management and biostatistics support.

Secondary review synthesized peer-reviewed literature, regulatory guidance documents, and public disclosures to contextualize technological advances and policy changes that affect outsourcing models. Cross-validation was performed through triangulation of qualitative insights and document analysis, and findings were stress-tested in scenario exercises that model supply chain disruptions, modality-specific scale-up challenges, and regulatory pathway variability. Quality control measures included methodological transparency, clear inclusion criteria for interviewees, and iterative review cycles with domain experts to refine conclusions and recommendations.

Concise synthesis highlighting the strategic takeaways, operational priorities, and essential considerations for outsourcing immunotherapy discovery and development

In conclusion, outsourcing in cancer immunotherapy discovery and development is becoming more strategic, specialized, and data-driven. Sponsors now expect external partners to provide integrated capabilities that span discovery to clinical stages, with strong emphasis on CMC process development, modality-specific assay development, and advanced analytics. Policy changes and supply chain dynamics have underscored the importance of geographical diversification and the need for resilient sourcing strategies that preserve program timelines and product quality.

Moving forward, organizations that align early with partners capable of co-designing experiments, enabling scalable manufacturing, and translating complex biological signals into regulatory-ready evidence will gain the most leverage. The path to successful outsourcing requires deliberate vendor selection, early integration of regulatory and data strategies, and investment in robust technical transfer and quality assurance practices. Adopting these approaches will reduce development risk, improve reproducibility, and position programs to capitalize on the accelerating innovation in immuno-oncology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Service Type

  • 8.1. Clinical Development Services
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
  • 8.2. Data Management And Biostatistics
    • 8.2.1. Bioinformatics
    • 8.2.2. Clinical Data Management
    • 8.2.3. Statistical Analysis
  • 8.3. Manufacturing Support
    • 8.3.1. CMC Optimization
    • 8.3.2. Process Development
  • 8.4. Preclinical Services
    • 8.4.1. Hit And Lead Discovery
    • 8.4.2. Lead Optimization
    • 8.4.3. Preclinical Safety Assessment
    • 8.4.4. Target Identification
  • 8.5. Regulatory Affairs Support
    • 8.5.1. IND Filing Support
    • 8.5.2. Regulatory Strategy Consulting

9. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Therapeutic Modality

  • 9.1. Cancer Vaccines
    • 9.1.1. Dendritic Cell Vaccines
    • 9.1.2. DNA Vaccines
    • 9.1.3. Peptide Vaccines
    • 9.1.4. RNA Vaccines
  • 9.2. CAR T Cell Therapy
    • 9.2.1. BCMA Targeted
    • 9.2.2. CD19 Targeted
  • 9.3. Checkpoint Inhibitors
    • 9.3.1. CTLA-4 Inhibitors
    • 9.3.2. PD-1 Inhibitors
    • 9.3.3. PD-L1 Inhibitors
  • 9.4. Cytokine Therapy
    • 9.4.1. Colony Stimulating Factors
    • 9.4.2. Interferons
    • 9.4.3. Interleukins
  • 9.5. Monoclonal Antibodies
    • 9.5.1. Chimeric
    • 9.5.2. Fully Human
    • 9.5.3. Humanized
    • 9.5.4. Murine
  • 9.6. Oncolytic Virus Therapy
    • 9.6.1. Adenovirus Based
    • 9.6.2. HSV Based
    • 9.6.3. Reovirus Based

10. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Workflow Stage

  • 10.1. Clinical Stage
    • 10.1.1. Phase I
    • 10.1.2. Phase II
    • 10.1.3. Phase III
  • 10.2. Development Stage
    • 10.2.1. IND Enabling Studies
    • 10.2.2. Preclinical Development
  • 10.3. Discovery Stage
    • 10.3.1. Hit Discovery
    • 10.3.2. Hit Validation
    • 10.3.3. Lead Discovery
    • 10.3.4. Target Identification
  • 10.4. Post Approval Stage
    • 10.4.1. Pharmacovigilance
    • 10.4.2. Phase IV Studies

11. Cancer Immunotherapy Drug Discovery Outsourcing Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Biotechnology Companies
  • 11.3. Government Research Institutes
  • 11.4. Pharmaceutical Companies

12. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Immunotherapy Drug Discovery Outsourcing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cancer Immunotherapy Drug Discovery Outsourcing Market

16. China Cancer Immunotherapy Drug Discovery Outsourcing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. BPS Bioscience, Inc.
  • 17.6. Celentyx Ltd.
  • 17.7. Charles River Laboratories International, Inc.
  • 17.8. Covance, Inc.
  • 17.9. Crown Bioscience, Inc.
  • 17.10. Curia Inc.
  • 17.11. Dalton Pharma Services
  • 17.12. DiscoverX Corporation
  • 17.13. Eurofins Scientific
  • 17.14. Evotec SE
  • 17.15. Explicyte
  • 17.16. Genscript Biotech Corporation
  • 17.17. HD Biosciences Co., Ltd.
  • 17.18. Horizon Discovery Group PLC
  • 17.19. ImmunXperts SA
  • 17.20. Jubilant Life Sciences Limited
  • 17.21. Labcorp
  • 17.22. Oncodesign Precision Medicine Opm SA
  • 17.23. Personalis, Inc.
  • 17.24. Promega Corporation
  • 17.25. STC Biologics Inc.
  • 17.26. TCG Lifesciences Pvt. Limited
  • 17.27. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATISTICAL ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATISTICAL ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY STATISTICAL ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CMC OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CMC OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CMC OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT AND LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT AND LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT AND LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SAFETY ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SAFETY ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SAFETY ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND FILING SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND FILING SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND FILING SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY CONSULTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY CONSULTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY CONSULTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DENDRITIC CELL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DENDRITIC CELL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PEPTIDE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PEPTIDE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY RNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BCMA TARGETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BCMA TARGETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BCMA TARGETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CD19 TARGETED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CD19 TARGETED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CD19 TARGETED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLONY STIMULATING FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLONY STIMULATING FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COLONY STIMULATING FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERFERONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERFERONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERLEUKINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY INTERLEUKINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MURINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MURINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MURINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ADENOVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ADENOVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ADENOVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HSV BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HSV BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HSV BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REOVIRUS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REOVIRUS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REOVIRUS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND ENABLING STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND ENABLING STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY IND ENABLING STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY HIT VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY LEAD DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE IV STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE IV STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHASE IV STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 215. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 216. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 218. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 219. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 220. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 222. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 224. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 225. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 226. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2032 (USD MILLION)
  • TABLE 228. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DISCOVERY STAGE, 2018-2032 (USD MILLION)
  • TABLE 229. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY POST APPROVAL STAGE, 2018-2032 (USD MILLION)
  • TABLE 230. AMERICAS CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CLINICAL DEVELOPMENT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT AND BIOSTATISTICS, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MANUFACTURING SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 236. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SUPPORT, 2018-2032 (USD MILLION)
  • TABLE 238. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY THERAPEUTIC MODALITY, 2018-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CANCER VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CAR T CELL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY CYTOKINE THERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, 2018-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA